Inactivated Influenza Vaccine for Hemophilia Patients
Patients with hemophilia should receive the inactivated influenza vaccine (IIV) administered subcutaneously, NOT the live attenuated intranasal vaccine (LAIV). 1
Route of Administration
The critical consideration for hemophilia patients is avoiding intramuscular injections due to bleeding risk. All influenza vaccinations should be given subcutaneously rather than intramuscularly to minimize the risk of hematoma formation at the injection site 2. This is the standard approach for all routine vaccinations in patients with bleeding disorders.
Vaccine Type Selection
- Use inactivated influenza vaccine (trivalent or quadrivalent IIV) - This is safe and appropriate for all hemophilia patients
- Avoid live attenuated intranasal vaccine (LAIV/FluMist) - While not specifically contraindicated for hemophilia alone, the subcutaneous route is preferred for consistency and safety in this population
Timing and Frequency
- Annual vaccination is recommended for all patients with hemophilia 2
- Vaccination should occur during the standard influenza season (typically fall/early winter)
- No special timing relative to factor replacement therapy is required for routine vaccination
Age-Specific Considerations
For children with hemophilia:
- Begin annual influenza vaccination at age 6 months (minimum age for IIV) 3
- Children aged 6 months through 8 years receiving influenza vaccine for the first time require 2 doses, administered at least 4 weeks apart
- Subsequent years require only 1 dose annually
Important Caveats
Watch for rare complications: While extremely uncommon, there is one case report of acquired hemophilia-A (autoantibody development against factor VIII) following influenza vaccination 4. However, this should not deter vaccination, as the benefits far outweigh this theoretical risk.
No factor replacement needed: Routine subcutaneous influenza vaccination does not require prophylactic factor replacement therapy in most hemophilia patients, as the bleeding risk from subcutaneous injection is minimal.
The evidence consistently supports that hemophilia patients can be safely immunized against influenza using standard inactivated vaccines via the subcutaneous route, providing important protection against a potentially serious respiratory infection that could complicate their bleeding disorder management.